Answers are grounded in this paper and cite their sources.
Glioblastoma (GBM) is a formidable cancer characterized by significant morbidity and mortality owing to restricted therapeutic alternatives. Gemcitabine (GEM) is frequently utilized; however, its efficacy is diminished by chemoresistance. Investigations underscore XAV939, a small-molecule inhibitor, as a potential anti-cancer therapeutic for GBM. This study explored the combination therapy of GEM and XAV939, revealing that their concurrent use significantly increased the BAX to Bcl2 ratio and enhanced caspase-3 and -9 activities. This combination therapy inhibited GBM tumor growth, induced apoptosis, and halted cell survival. The duo also suppressed autophagy by reducing protein levels of Beclin1, Lc3II, and P62. Furthermore, the synergistic effect of GEM and XAV939 on tumor growth inhibition was superior to that of GEM alone, as XAV939 obstructed endothelial vascular invasion, necrosis, and tumor proliferation. These results suggest that XAV939 could be a valuable therapeutic agent for GBM treatment in conjunction with GEM.
No takes yet. Share an insight, caveat, or question.
Badreh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: